AAIC 2026: Cellular Pathophysiology and Neurodegeneration Biomarkers in Alzheimer's Disease

AAIC 2026: Cellular Pathophysiology and Neurodegeneration Biomarkers in Alzheimer's Disease

Conference: AAIC 2026 | Dates: July 12-15, 2026 | Location: Excel London, UK

Overview

AAIC 2026: Cellular Pathophysiology and Neurodegeneration Biomarkers in Alzheimer's Disease

Conference: AAIC 2026 | Dates: July 12-15, 2026 | Location: Excel London, UK

Overview

The Alzheimer's Association International Conference (AAIC) 2026 featured extensive programming on the cellular pathophysiology of Alzheimer's disease, including advances in neurodegeneration biomarkers such as neurofilament light chain (NfL), phosphorylated tau at threonine 181 (p-tau181), and p-tau217, as well as synaptic dysfunction biomarkers and mechanisms of neuronal death. These biomarkers provide critical insight into disease mechanisms and enable tracking of disease progression and therapeutic response.

The cellular pathophysiology of AD involves multiple interconnected processes:

• Amyloid-beta accumulation and plaque formation
• Tau hyperphosphorylation and neurofibrillary tangle formation
• Synaptic dysfunction and loss
• [Neuroinflammation](/mechanisms/neuroinflammation) Neuronal death

Neurodegeneration Biomarkers

Neurofilament Light Chain (NfL)

NfL is a marker of axonal damage and neurodegeneration that reflects the breakdown of neuronal Processes[@khalil2024]:

• Source: Intermediate filament protein in neuronal axons
• Detectable in: CSF and blood (plasma/serum)
• Clinical significance: Non-specific marker of neuronal damage - elevated in AD, PD, ALS, FTD, and other neurodegenerative conditions
• Correlation: Correlates with disease severity and progression rate
• Longitudinal tracking: Serial measurements track disease progression

• Differential diagnosis: Distinguishing AD from other dementias
• Prognostication: Predicting progression rate in MCI and early AD
• Clinical trial endpoints: Serving as pharmacodynamic markers
• Treatment monitoring: Tracking response to disease-modifying therapies

Phosphorylated Tau 181 (p-tau181)

p-tau181 is the most validated tau biomarker for AD, reflecting tau pathology specifically[@karikari2020]:

• Source: Tau protein phosphorylated at threonine 181
• Detectable in: CSF and blood
• Clinical specificity: Highly specific for AD-type tau pathology
• Diagnostic performance: AUC 0.90-0.95 for AD vs. controls
• Correlation: Correlates with cortical tau burden on PET

• Blood-based testing: Fully automated plasma p-tau181 assays now available
• Clinical implementation: FDA De Novo classification pathway
• Population screening: Feasibility in primary care settings
• Treatment monitoring: Pharmacodynamic marker for anti-amyloid therapies

Phosphorylated Tau 217 (p-tau217)

p-tau217 has emerged as the most specific blood-based AD biomarker[@palmqvist2024]:

• Source: Tau protein phosphorylated at threonine 217
• Detectable in: CSF and blood
• Specificity: Higher specificity than p-tau181 for AD
• Diagnostic performance: AUC >0.95 in some assays
• Correlation: Strong correlation with amyloid PET (r = 0.82-0.89)

• Automated assays: Fully automated platforms clinical-ready
• Early detection: Detectable before clinical symptoms
• Prognostic value: Predicts MCI-to-AD progression
• Combination panels: p-tau217 + p-tau181 for enhanced accuracy

Synaptic Dysfunction Biomarkers

Synaptic loss is the strongest correlate of cognitive decline in AD[@selkoe2024]. Several biomarkers specifically track synaptic dysfunction:

Neurogranin

Neurogranin is a postsynaptic protein that serves as a specific marker of synaptic degeneration[@kvartsberg2015]:

• Source: RC3 gene, enriched in dendritic spines
• Detectable in: CSF
• Specificity: Specific to AD (not elevated in other dementias)
• Clinical utility: Correlates with cognitive decline in prodromal AD
• Longitudinal changes: Tracks synaptic loss over time[@mattsson2018]

• Combination with p-tau: Enhanced diagnostic accuracy
• Progression tracking: Neurogranin trajectory predicts rate of cognitive decline
• Trial enrichment: Used for patient selection in synaptic-targeted trials

Other Synaptic Biomarkers

Additional synaptic biomarkers highlighted:

| Biomarker | Target | Clinical Utility |
|----------|-------|-----------------|
| Snap-25 | Presynaptic terminal | Synaptic release marker |
| Synaptophysin | Synaptic vesicles | Density marker |
| Neuroplexin-1 (NPTX1) | Synaptic excitotoxicity | Early synaptic dysfunction |
| SV2A | Synaptic vesicles | PET imaging target |

Neuronal Death Mechanisms

Apoptotic Pathways

Neuronal death in AD involves multiple cell death pathways:

• Intrinsic apoptosis: Mitochondrial dysfunction triggers caspase-9 activation
• Extrinsic apoptosis: Death receptor signaling (Fas/TNFR1)
• ER stress: Unfolded protein response leads to CHOP-mediated apoptosis
• Oxidative stress: ROS accumulation damages neurons

Necrotic and Autophagic Cell Death

• Necrosis: Occurs in advanced disease stages
• Autosis: Autophagy-related cell death
• Parthanatos: PARP1-dependent cell death

Tau-Mediated Neurotoxicity

• Hyperphosphorylated tau: Lose microtubule binding, gain toxic functions
• Tau oligomers: Spread between neurons, propagate pathology
• Tau fibrils: Incorporate into neurofibrillary tangles

Biomarker Integration: AT(N) Framework

The AT(N) biomarker classification system integrates these biomarkers:

| Category | Biomarkers | What it Measures |
|----------|-----------|----------------|
| A (Amyloid) | Aβ42/40, PET | Amyloid pathology |
| T (Tau) | p-tau181, p-tau217, tau PET | Tau pathology |
| (N) Neurodegeneration | NfL, t-tau, FDG-PET | Neuronal damage |

Biomarker Sequencing in AD

The AT(N) framework reflects the temporal sequence of AD pathology:

This sequencing enables:

• Early detection: Identifying AD before symptoms
• Staging: Determining disease stage
• Prognostication: Predicting progression rate
• Treatment monitoring: Tracking response to therapy

Clinical Implementation

Current Clinical Use

These biomarkers are increasingly used in clinical practice:

• Specialty centers: CSF and blood biomarkers for differential diagnosis
• Clinical trials: Enrichment and endpoint selection
• Population screening: Research and screening programs

Emerging Applications

AAIC 2026 highlighted emerging applications:

• Primary care screening: Blood-based biomarkers for primary care use
• Digital integration: Combining with cognitive assessments
• Multi-analyte panels: Simultaneous measurement
• Precision medicine: Individualized biomarker profiles

Key Takeaways

See Also

• [Neurofilament Light Chain (NfL) - Biomarker](/biomarkers/neurofilament-light-chain-nfl)
• [Phosphorylated Tau 181 (p-tau 181)](/biomarkers/p-tau-181)
• [Phosphorylated Tau 217 (p-tau 217)](/biomarkers/p-tau-217)
• [Neurogranin (Ng) - Synaptic Biomarker](/biomarkers/neurogranin)
• [Synaptic Biomarkers in AD](/biomarkers/synaptic-biomarkers-alzheimers)
• [AT(N) Biomarker Classification](/biomarkers/atn-biomarker-classification-ad)
• [AAIC 2026 Fluid Biomarkers](/events/aaic-2026/fluid-biomarkers)
• [AAIC 2026 Synaptic Function Preservation](/events/aaic-2026/synaptic-function-preservation)

References